Merrimack Pharmaceuticals Inc.
101 Binney Street
Cambridge
Massachusetts
02142
United States
Tel: 617-441-1000
Fax: 617-491-1386
Website: http://www.merrimackpharma.com/
Email: info@merrimackpharma.com
263 articles with Merrimack Pharmaceuticals Inc.
-
In the wake of a Complete Response Letter issued by the FDA, Trevana, Inc. is slashing one-third of its workforce. On Wednesday, Merrimack Pharmaceuticals also announced it was terminating 60 percent of its staff as the company narrows its research and development focus.
-
Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
11/7/2018
Company to initiate corporate restructuring, including ~60% reduction in force and significant reduction in operating expenses; potential to extend runway into at least 2H 2022 to preserve ability to capture Ipsen milestones
-
Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call
10/31/2018
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2018 investor conference call and webcast at 8:30 am ET on Wednesday, November 7, 2018.
-
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
10/19/2018
MM-121 did not improve progression free survival (PFS) in patients with non-small cell lung cancer (NSCLC)
-
The trial was evaluating MM-121 in combination with docetaxel, a chemotherapy drug, in patients with heregulin positive non-small cell lung cancer (NSCLC).
-
Merrimack Receives $5 Million Milestone Payment from Shire
9/20/2018
Merrimack Pharmaceuticals, Inc. today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack's asset sale to Ipsen in 2017.
-
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
9/6/2018
Merrimack Pharmaceuticals, Inc. today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead investigational drug candidate, MM-121, in patients with heregulin positive NSCLC.
-
The U.S. Securities and Exchange Commission has leveled charges at a former Sangamo Therapeutics Inc. executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”
-
Merrimack Reports Second Quarter 2018 Financial Results
8/7/2018
$18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources
-
Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals (MACK) were convicted of insider trading by a federal grand jury in Boston.
-
Merrimack Secures $25 Million Debt Facility with Hercules Capital
7/2/2018
Non-dilutive financing strengthens cash positio
-
Although it’s great to report on successful clinical trial results, the reality is that only about one in 10 drugs make it to approval. With that number in mind, here are a couple companies reporting problematic clinical trials today.
-
Gemini Therapeutics Strengthens Senior Leadership Team with Key Appointments and Promotion
5/30/2018
Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.
-
Merrimack Announces Timing of First Quarter 2018 Investor Conference Call
5/1/2018
Merrimack Pharmaceuticals, Inc. announced that the company will host its first quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, May 8, 2018.
-
Merrimack Pharmaceuticals announced it is expanding enrollment in a Phase II lung cancer study.
-
Merrimack Provides Business Update and Reports 2017 Financial Results
3/12/2018
Merrimack Pharmaceuticals Inc. announced its fourth quarter and full year 2017 financial results for the period ended December 31, 2017.
-
Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
3/12/2018
Randomized Phase 2 study accrual raised to 100 patients; data still expected later this year.
-
Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer
2/26/2018
MM-121 is a fully human monoclonal antibody that targets HER3 signaling and is designed to overcome cancer cells' resistance to the effects of anti-tumor therapies.
-
This is definitely a list few, if any, companies want to be on.
-
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
11/30/2017
Dr. Demetri, a world-renowned expert in the clinical translation of innovative treatment strategies for cancer, replaces John Mendelsohn, M.D., who is retiring from the Board.